International comparative study on high-value drugs payment system and its implications for China
10.3969/j.issn.1674-2982.2015.12.009
- VernacularTitle:高值药物支付机制的国际比较及启示
- Author:
Yuxiao ZHANG
;
Dan CUI
;
Zongfu MAO
- Keywords:
High-value drugs;
Payment system;
Drug price negotiation
- From:
Chinese Journal of Health Policy
2016;9(12):44-49
- CountryChina
- Language:Chinese
-
Abstract:
Objective:The aim of the present study was to conduct an international comparison of the high-val-ue drugs payment systems of some selected countries, and introduce them to the Chinese context. Australia, America and Germany's high-value drugs payment systems were selected to serve as references for China. Methods: The main content and characteristics of three countries' payment systems were analyzed in four aspects:expenditure copayment mode, paid-scope selection, drug price negotiation, and drug rational use management which were then compared with the Chinese status. Results:Through the difference in healthcare system tradition, the above countries have vari-ous copayment mode, but they all select paid-drug by cost-effectiveness analysis with corresponding control measures. Conclusions:China should: establish a co-payment mode for the high-value drugs on the basis of a critical illness medical insurance found;build a national pharmaco-economic evaluation index system and improve the national nego-tiation superiority, while emphasizing on risk-sharing mechanism; and make series specifications to guarantee the drug to be rationally used.
